通过mTORC1/SASP路径,用于持续的DEPTOR传递和IDD延迟的外体向注射水凝
Hui Lu1, Zhiming Liu2, Shuo Han3
1Department of Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China; Qingdao Medical College, Qingdao University, Qingdao, 266000, China; Wuhan Liu Sanwu Bone Injury Hospital of Traditional Chinese medicine, Wuhan, 430000, China.
International journal of biological macromolecules
|November 8, 2025
概括
一种新型的液凝提供DEPTOR载荷外体,通过抑制衰老相关分泌表型 (SASP) 和炎症,有效治疗椎间盘退化 (IDD),提供了一个有前途的治疗策略.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 细胞生物学 细胞生物学
背景情况:
- 椎间盘退化 (IDD) 被衰老的核脉细胞和与衰老相关的分泌表型 (SASP) 加剧.
- 含有DEP域的mTOR相互作用蛋白 (DEPTOR) 可以通过调节哺乳动物目标的拉巴胺素复合物1 (mTORC1) 途径来抑制SASP和减轻IDD.
研究的目的:
- 开发一种新型的水凝载体,用于持续释放装载DEPTOR的外体 (EXOs),用于治疗IDD.
- 克服传统EXO载体的局限性,例如细胞毒性和低降解性.
主要方法:
- 构建可注射的氧化基酸盐/甲基酸盐 (OSA/CMCS) 水凝封装尿液干细胞衍生的EXO.
- 用于持续DEPTOR释放和EXO传递的水凝的特性.
- 在刺穿诱导的IDD大鼠模型中评估水凝的疗效.
主要成果:
- 该OSA/CMCS@EXO水凝证明了高效和稳定的EXO输送与持续的DEPTOR释放.
- 在大鼠中,用水凝治疗显著缓解了椎间盘炎症,并减缓了IDD进展.
- 证实DEPTOR/mTORC1/SASP通路是IDD治疗的关键目标.
结论:
- 新的OSA/CMCS@EXO水凝通过准DEPTOR/mTORC1/SASP通路,为IDD提供了一种有效的治疗策略.
- 这种可注射的水凝系统在各种疾病应用中显示出基于外体的治疗方法的巨大潜力.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
175
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
175
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
186
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
186
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
216
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
216
01:21Intrauterine Drug Delivery Systems
170
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
170